Although this evidence should be validated in vivo through FAK1 genetic ablation in order to circumvent possible off-target effects of pharmacological inhibition, concomitant silencing of FAK1 and AMBRA1 in vitro confirmed the reduced propensity of melanoma cells to migrate and invade. The gene discussed is PTK2; the disease is melanoma.